Dipexium Pharmaceuticals, Inc, New York, New York, recently announced it has initiated patient enrollment in the second of 2 phase 3 clinical trials, identified as OneStep-1 and OneStep-2, to evaluate its novel, broad-spectrum, topical antibiotic peptide for the treatment of patients with mild infections of diabetic foot ulcers. The trials' main objective is to establish the clinical effectiveness and safety of topical Locilex plus standard local wound care as compared with placebo cream plus standard local wound care, in the treatment of mild diabetic foot infections. According to the company, OneStep-1 and OneStep-2 are identical, double-blind, placebo-controlled clinical trials that will be conducted simultaneously, and each enrolls approximately 180 patients at 20 separate centers in the United States.

[black up pointing small triangle] Information:http://www.dipexiumpharmaceuticals.com